Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Health ProductsUEEC +2.61% Debt-to-EBITDA is -2.12 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 469 Medical Devices & Instruments companies, United Health Products ranks worse than 213219.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for United Health Products's Debt-to-EBITDA or its related term are showing as below:
UEEC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.69 Med: -0.33 Max: -0.01
Current: -1.69
During the past 13 years, the highest Debt-to-EBITDA Ratio of United Health Products was -0.01. The lowest was -1.69. And the median was -0.33.
UEEC's Debt-to-EBITDA is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs UEEC: -1.69
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
United Health Products Debt-to-EBITDA Related Terms
United Health Products Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for United Health Products's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UEEC vs FEMY, BNGO, RGNT: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, United Health Products's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Health Products Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, United Health Products's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where United Health Products's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
United Health Products (UEEC) has a Debt-to-EBITDA of -2.12 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on United Health Products. According to the industry distribution chart, United Health Products ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is United Health Products' Debt-to-EBITDA too high?
United Health Products' current Debt-to-EBITDA is -2.12. Based on the distribution chart, United Health Products ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does United Health Products' Debt-to-EBITDA compare to FEMY and BNGO?
According to the Medical Devices & Instruments industry distribution chart, United Health Products ranks #999999 out of 469 companies for Debt-to-EBITDA. This places United Health Products in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on United Health Products. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Health Products's current Debt-to-EBITDA is -2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Health Products stock overvalued right now?
United Health Products (UEEC) has a current Debt-to-EBITDA of -2.12. The current Debt-to-EBITDA is -2.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For United Health Products (UEEC), the current Debt-to-EBITDA is -2.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
United Health Products Inc develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Its gauze product, CelluSTAT, is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. The company are in the process of seeking regulatory approval to sells hemostatic gauze product line into the U.S. Class III and European CE Mark human surgical markets. The company operates as a single operating segment, focusing on the development and commercialization of medical devices, particularly its patented hemostatic gauze, CelluSTAT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UEEC has been successfully added to your 
